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OBJECTIVES: Inhaled corticosteroids can cause oropharyngeal
adverse events (OAEs). We investigated the direct costs of treat-
ing oral candidiasis and hoarseness OAEs in Australia (costs
$AUD). METHODS: We assumed 4% fewer OAEs in patients
treated with ciclesonide (CIC), compared to ﬂuticasone propi-
onate (FP), based on data from a 12-week, randomized, double-
blind clinical trial in patients with moderate asthma (comparable
efﬁcacy; OAE rate: CIC [400 μg/day] 0.5%; FP [500 μg/day]
4.5%; rate difference (RD) 4%, 95% CI: 1.04%–6.95%). Cost-
ings were done based on resource sparing and resource intensive
assumptions. RESULTS: The resource sparing model assumed:
1.9 doctor visits ($30.85 per visit) and 1.9 nystatin treatments
($9.08 per treatment) to diagnose and treat OAE. The estimated
treatment cost per OAE was $75.87. The average cost saving per
patient treated with CIC per 12-week period was $3.03 ($75.87
× 4%). The cost saving per prescription with CIC per 12-week
period was $2.02 ($3.03/1.5). Sensitivity analyses showed
savings per prescription of $0.53 to $3.52 (using lower and
upper 95% CI for OAE RD). The resource intensive model
assumed: 3.4 doctor visits ($30.85 per visit) and 3.4 nystatin
treatments ($9.08 per treatment) to diagnose and treat OAE; 
1.0 specialist visit ($72.60) and 1.0 ketoconazole treatment
($38.58). The estimated treatment cost per OAE was $246.94.
The average cost saving per patient treated with CIC per 12-
week period was $9.88 ($246.94 × 4%). The cost saving per pre-
scription with CIC per 12-week period was $6.59 ($9.88/1.50).
Sensitivity analyses showed savings per prescription of $1.71 to
$11.44 (using lower and upper 95% CI for OAE RD). CON-
CLUSIONS: We believe the improved safety proﬁle of CIC
would reduce resource use associated with treating OAEs and
have favorable long-term clinical and economic outcomes.
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OBJECTIVE: The study was undertaken to examine the impact
of medication adherence on health care utilization and costs. 
In sub-analyses the differences between patients who switch
between different regimes or agents compared to those, who con-
tinuing to take their existing medication were analysed.
METHOD: This retrospective observational study included
1459 patients (°Y´18) with asthma. From January 2001 through
December 2004, the medication possession ratio (MPR)was used
to assess adherence. Data on resource utilization including physi-
cian visits and hospital referrals was collected. Unit costs at 2005
prices were applied to this data to estimate the mean annual costs
per patient. Indirect costs due to workdays lost were also con-
sidered. RESULTS: Of 1459 patients who are under anti-asth-
matic therapy, 300 were taking an inhaled long-acting beta2
agonist (LABA), 278 patients an inhaled corticosteroid (ICS) and
94 patients were using both (LABA + ICS). Another 457 and 424
patients were receiving the ﬂuticasone/salmeterol and budes-
onide/formoterol ﬁxed combination, respectively. About 30% of
the patients switch between inhaled medications. This cohort
showed a higher mean adherence (62%) compared to the
patients continuing to take their existing inhaler (56%). Also the
proportion of patients achieving an adequate adherence level was
higher (46% versus 39%). However, compared with the patients
who stick to their medications, those who switch between
regimes or agents had more unscheduled physician visit (1,9 per
switching vs. 1,59 per existing patient) and more work-loss days
(14,1 days per switching vs. 6,34 days per existing patient).
When comparing both the direct costs and indirect costs, switch-
ing patients caused higher costs per patient. CONCLUSIONS:
Even though the patients who switch show a better adherence
with their treatment, they cause higher mean direct and indirect
costs per patient per observation year. This ﬁnding indicates that
it might be better to adjust patients successfully to one product.
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OBJECTIVES: To compare the use of secondary drugs (SABA-
Short acting beta adrenergic agents, formoterol fumarate dihy-
drate and formoterol fumarate) correlated to the use of primary
drugs (ﬂuticasone/salmeterol and budesonide/formoterol combi-
nation as a single inhaler), using a claims ratio measurement unit,
in the management of asthma. METHODS: A retrospective
analysis has been conducted using a Canadian health care insur-
ance claims database. In order to obtain the claims ratio unit,
the database review analysed the number of patients (claimants)
that used the above-mentioned medication. The main criteria for
selecting the claimants were: Patients with at least 2 claims for
one of the main target drugs during the index period. Active
patients: who had a claim for any drug at least 6 months before
and 12 months after their ﬁrst claim of the target drug during
the index period. Patients that did not switch therapy between
the main target drugs during the index period. The perspective
was of the third party payer. RESULTS: The use of budes-
onide/formoterol combination as a single inhaler as a primary
drug in the management of asthma, determined a decrease in the
number of claims and use of secondary drugs (one claim of
budesonide/formoterol combination as a single inhaler deter-
mined 0.71 claims of fenoterol HBR vs. 0.86 with ﬂuticasone/sal-
meterol vs. 1.28 with budesonide, and vs. 0.92 with ﬂuticasone
propionate), formoterol fumarate dyhidrate (0.53 vs. 0.59 vs.
1.16 vs. 0.95), and formoterol fumarate (0.44 vs. 0.47 vs. 1.43
vs. 0.83). The claims analysis shows a decrease in the claims ratio
and costs of secondary drugs and overall treatment costs when
using budesonide/formoterol combination as a single inhaler.
CONCLUSIONS: The budesonide/formoterol combination as a
single inhaler can represent an economically advantageous
asthma treatment option compared with other primary drugs.
PAA9
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OBJECTIVE: Generic-only drug-beneﬁt coverage is increasingly
common. There are no generic inhaled corticosteroids (ICS),
therefore, patients with generic-only coverage pay full-price for
ICS drugs. We examined the impact of losing brand-coverage on
